Literature DB >> 32008437

Thiazide Exposure and Cardiovascular Risk in Type 2 Diabetes Mellitus: A Point of Clarification.

Steven M Smith1,2, Almut G Winterstein2, Carl J Pepine3, Rhonda M Cooper-DeHoff1,3.   

Abstract

A recently published analysis in Hypertension suggests that thiazide use, versus nonuse, is associated with excess risk of adverse cardiovascular outcomes in patients with diabetes mellitus enrolled in the ACCORD trial (Action to Control Cardiovascular Risk in Diabetes). Here, we replicate these findings using the same publicly available datasets and following their reported methods. We further show that possible misclassification of thiazide exposure exists in the original analysis. We perform alternative analyses that correct for this misclassification to highlight the impact that misclassification can have on observed associations between an exposure (eg, thiazides) and outcomes (eg, stroke and major adverse cardiovascular events).

Entities:  

Year:  2020        PMID: 32008437      PMCID: PMC7035168          DOI: 10.1161/HYPERTENSIONAHA.119.14447

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  2 in total

1.  Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

Authors:  William C Cushman; Richard H Grimm; Jeffrey A Cutler; Gregory W Evans; Sarah Capes; Marshall A Corson; Laurie S Sadler; Michael H Alderman; Kevin Peterson; Alain Bertoni; Jan N Basile
Journal:  Am J Cardiol       Date:  2007-04-16       Impact factor: 2.778

2.  Thiazide Use and Cardiovascular Events in Type 2 Diabetic Patients With Well-Controlled Blood Pressure.

Authors:  Tetsuro Tsujimoto; Hiroshi Kajio
Journal:  Hypertension       Date:  2019-11-04       Impact factor: 10.190

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.